Medtronic PLC (MDT) Fair Value & Analysis

Healthcare · US · Market cap $106B · ISIN IE00BTN1Y115

What is Medtronic PLC really worth?

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

What matters now

• The price sits above even our optimistic bull case ($87.04). The favourable scenario is already priced in.
• Solid but not exceptional quality (68/100) and above fair value, neither a clear bargain nor a standout compounder.
• A fairly wide model range ($35.13 to $87.04) leaves room in how you read the outcome.

Price vs Fair Value (5 years)

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 29, 2026.

How to read this chart

60‑month range $63.45 – $115.57 · fair‑value band $35.13 – $87.04 · the $93.10 price screens above the $65.57 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Aug 29, 2026.

Full chart & analysis →

Which stocks are undervalued right now? Check free Discover now →

Analysis

Medtronic PLC (MDT) currently trades at $93.10, while our model-based Fair Value estimate is $65.57, implying the stock looks roughly 42.0% overvalued today. The Quality Score stands at 68/100 (solid quality), in the Healthcare sector. Bull case: the Growth Earnings group reads highest at a median of $75.19 per share, and 0 of the 26 models we run sit above the $93.10 price. Bear case: the Asset-Based group reads lowest at $25.89, and 26 of the 26 models stay below the price. Evidence for this calculation is high.

Over the trailing twelve months, Medtronic PLC generated revenue of $36.4B at a net margin of 13.2%. Revenue grew 9.9% year over year. It earns a return on equity of 9.9%. Net debt stands at $26.0B. Fundamentals as of Aug 29, 2026

Our scenario range runs from $35.13 (bear case) to $87.04 (bull case); at $93.10, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The last reported earnings sit well below what analysts expect (earnings in transition, for example after write-downs or an earnings dip); whether the stock is cheap or expensive hinges on the expected recovery actually arriving. Read the fair value with that caveat. The share trades about 11% below its 52-week high and 27% above its 52-week low, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at −34% fair-value upside, at −30%, MDT screens cheaper than that median.

Fair Value models

This estimate rests on fiscal year 2026 figures, and about 4 months have passed since. In that time the company retained roughly $0.3121 per share, which is 0.5 % of the fair value. The fair value deliberately does not add this in: the models value reported figures, not a projection.

Each model estimates fair value its own way; the Fair Value above is the evidence-weighted, family-balanced blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small. Every input is real reported data, nothing guessed.

Widest divergence: Growth Earnings ($75.19) versus Asset-Based ($25.89). Highest evidence: FCF DCF (77).

Key figures & financial health

Quality Score breakdown

About the company

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients in the United States, Ireland, and internationally.

Full company description

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients in the United States, Ireland, and internationally. The Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accessories, and transcatheter pulmonary valves, and percutaneous coronary intervention products, percutaneous angioplasty balloons, and other products. The Neuroscience Portfolio segment offers medical devices and implants, biologic solutions, spinal cord stimulation and brain modulation systems, implantable drug infusion systems, and interventional products, as well as nerve ablation system under the Accurian name. The segment offers its products for spinal surgeons, neurosurgeons, neurologists, pain management specialists, anesthesiologists, orthopedic surgeons, urologists, urogynecologists, and interventional radiologists, as well as ear, nose, and throat specialists, and energy surgical instruments. The Medical Surgical Portfolio segment offers surgical stapling devices, vessel sealing instruments, wound closure and electrosurgery products, AI-powered surgical video and analytics platform, robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology products, gastrointestinal and hepatologic diagnostics and therapies, and therapies to treat diseases and conditions, and patient monitoring and airway management products. The Diabetes Operating Unit segment provides insulin pumps and consumables, continuous glucose monitoring systems and sensors, and InPen, a smart insulin pen. Medtronic plc was founded in 1949 and is headquartered in Galway, Ireland.

Company description, as reported by the company or data provider.

Revenue & earnings trend

FY2022 – FY2026 · reported fiscal years

Medtronic PLC reported revenue of $36.4B in FY2026 versus $31.7B in FY2022, a compound +3.5%/yr. Reported net income was $4.8B in FY2026, compounding −1.2%/yr from FY2022.

MDT screens 42% overvalued. Compare with Abbott Laboratories, →

Recent news

External third-party headlines (Yahoo Finance, Reuters and others), not an editorial selection.

• Medtronic Q1 earnings on deck: What to expect Seeking Alpha · Aug 31, 2026
• Brokers Suggest Investing in Medtronic (MDT): Read This Before Placing a Bet Yahoo Finance · Aug 31, 2026

Peer Group

Medical Devices · 351 stocks

How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.

Valuation Multiples vs Medical Devices median · lower = cheaper

Strength profile in five axes (Snowflake)

Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.

VALUE 0: the price sits above our fair-value range.

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

Similar stocks

10 more Medical Devices stocks, each showing price versus our Fair Value estimate (as of Aug 29, 2026).

Explore undervalued stocks

More undervalued Healthcare stocks →

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

Discover tools

Frequently asked questions